[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Breast Cancer Therapeutics Market [(By Drug Type - HER2 Inhibitors, CDK4/6 Inhibitors & Aromatase Inhibitors; By Region – North America (The US), Europe (Germany) & Asia Pacific (Japan)] Outlook 2025

April 2019 | 90 pages | ID: GD7538D9893EN
Rockville Research

US$ 1,100.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Breast cancer therapeutics market has witnessed advent of innovative novel therapies such as combination of PARP inhibitors and CDK inhibitors. Advent of personalized breast cancer therapies is also expected to emerge as a game-changer in the industry.

The report “Global Breast Cancer Therapeutics Market [(By Drug Type - HER2 Inhibitors, CDK4/6 Inhibitors & Aromatase Inhibitors; By Region – North America (The US), Europe (Germany) & Asia Pacific (Japan)] Outlook 2025” provides in-depth analysis of the current scenario, detailed market outlook of the global breast cancer therapeutics market overall as well as across various geographies. Regional analysis is done across major markets in North America, Europe and Asia Pacific.

The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global breast cancer therapeutics market. The report has been segmented as following:-

Geographical Coverage
  • North America
  • Europe
  • Asia Pacific
Key Vendors
  • Novartis International AG
  • Merck & Co. Inc.
  • GlaxoSmithKline plc
  • Sanofi Pasteur SA
  • Pfizer Inc.
  • Astellas Pharma
  • Dendreon Corporation
1. EXECUTIVE SUMMARY

2. RESEARCH METHODOLOGY

3. BREAST CANCER

3.1 Overview
  3.1.1 Causes
  3.1.2 Symptoms
  3.1.3 Stages
3.2 Types
  3.2.1 Hormone receptor (HR)-positive
  3.2.2 Human epidermal growth factor receptor 2 (HER2)-positive
  3.2.3 Triple negative breast cancer (TNBC)
3.3 Diagnosis & Treatment
  3.3.1 Diagnosis
  3.3.2 Treatment

4. MARKET ANALYSIS

4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
  4.2.1 Market Share by Stage
  4.2.2 Market Share by Type
  4.2.3 Market Share by Region

5. MARKET SEGMENTATION – DRUG TYPE

5.1 HER2 Inhibitors
  5.1.1 Overview
  5.1.2 Market Sizing (Actual & Forecasted)
5.2 CDK4/6 Inhibitors
  5.2.1 Overview
  5.2.2 Market Sizing (Actual & Forecasted)
5.3 Aromatase Inhibitors
  5.3.1 Overview
  5.3.2 Market Sizing (Actual & Forecasted)

6. REGIONAL ANALYSIS

6.1 North America
  6.1.1 Market Sizing (Actual & Forecasted)
  6.1.2 The US
    6.1.2.1 Market Sizing (Actual & Forecasted)
    6.1.2.2 Market Share by Drug Types
6.2 Europe
  6.2.1 Market Sizing (Actual & Forecasted)
  6.2.2 Germany
    6.2.2.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
  6.3.1 Market Sizing (Actual & Forecasted)
  6.3.2 Market by Nations
  6.3.3 Japan
    6.3.3.1 Market Sizing (Actual & Forecasted)
    6.3.3.2 Market Share by Drugs

7. MARKET DYNAMICS

7.1 Industry Trends & Developments
  7.1.1 Mergers & Acquisitions
  7.1.2 Emergence of Novel Therapies
  7.1.3 Advent of Personalized & Targeted Therapies
7.2 Growth Drivers
  7.2.1 Prevalence of Breast Cancer
  7.2.2 Ageing Population
  7.2.3 Rapid Changes in Lifestyle
  7.2.4 Increasing Public Awareness
7.3 Challenges
  7.3.1 Patent Expirations of Blockbuster Drugs
  7.3.2 Stringent Regulations
  7.3.3 Lack of Awareness in LICs
  7.3.4 High Prices of Therapies

8. COMPETITIVE LANDSCAPE

9. COMPANY PROFILES

9.1 F. Hoffman-La Roche AG
9.2 Novartis AG
9.3 Eli Lilly and Company
9.4 Pfizer Inc.
9.5 AstraZeneca PLC


More Publications